热门资讯> 正文
Arcitis表示Zoryve数据表明特应性皮炎可持续改善
2025-06-06 21:34
- New phase 3 data released by Arcutis Biotherapeutics (NASDAQ:ARQT) on Zoryve (roflumilast) found that the cream leads to durable improvement in of atopic dermatitis symptoms over the long term.
- Results from the open-label INTEGUMENT-OLE study found that in children 2-5 years old who saw disease clearance and then switched to proactive twice-weekly application Zoryve, the median duration of disease control was 238 days.
- For adults down to children age 6, the figure was 281 days.
- The new data will be presented at the 2025 Revolutionizing Atopic Dermatitis Conference.
More on Arcutis Biotherapeutics
- Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside
- Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript
- Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets
- Arcutis wins FDA nod for Zoryve foam for plaque psoriasis
- Arcutis outlines growth potential with ZORYVE expansions and market penetration
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
